Author response for "ER+, HER2– advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes"

crossref(2023)

引用 0|浏览5
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要